Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells

Leukemia

Volumn 24, Issue 3, 2010, Pages 613-622

  Azouz, A ^a,b,c   Wu, Y L ^d   Hillion, J ^a,b   Tarkanyi, I ^e   Karniguian, A ^a,b   Aradi, J ^e   Lanotte, M ^a,b   Chen, G Q ^d   Chehna, M ^c   Segal Bendirdjian, E ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

APL; Differentiation; Resistance; Retinoid; Telomerase; WT1

Indexed keywords

ONCOPROTEIN; RETINOIC ACID; RNA POLYMERASE II; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; WILMS TUMOR SUPPRESSOR PROTEIN 1;

ARTICLE; BINDING AFFINITY; CELL MATURATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EID: 77949425494     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.283     Document Type: Article

References (52)

1. Blackburn EH. Telomerases. Annu Rev Biochem 1992; 61: 113-129.
2. Nakamura TM, Cech TR. Reversing time: origin of telomerase. Cell 1998; 92: 587-590.
3. de Lange T. Telomeres and senescence: ending the debate. Science 1998; 279: 334-335.
4. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003; 21: 2034-2043.
5. Pendino F, Tarkanyi I, Dudognon C, Hillion J, Lanotte M, Aradi J, et al. Telomeres and telomerase: pharmacological targets for new anticancer strategies? Curr Cancer Drug Targets 2006; 6: 147-180.
6. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995; 269: 1236-1241.
7. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-795.
8. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-557.
9. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8: 137-142.
10. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999; 59: 826-830.
11. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999; 18: 1219-1226.
12. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998; 12: 1769-1774.
13. Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000; 19: 1485-1490.
14. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-224.
15. James L, Eisenman RN. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proc Natl Acad Sci USA 2002; 99: 10429-10434.
16. Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res 2005; 33: 6850-6860.
17. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 2007; 35: 7372-7388.
18. Takakura M, Kyo S, Inoue M, Wright WE, Shay JW. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 2005; 25: 8037-8043.
19. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113: 881-889.
20. Fujimoto K, Kyo S, Takakura M, Kanaya T, Kitagawa Y, Itoh H, et al. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res 2000; 28: 2557-2562.
21. Oh S, Song Y, Yim J, Kim TK. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem 1999; 274: 37473-37478.
22. Wang S, Zhu J. Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 2003; 278: 18842-18850.
23. Wang S, Zhu J. The hTERT gene is embedded in a nuclease-resistant chromatin domain. J Biol Chem 2004; 279: 55401-55410.
24. Wang S, Zhao Y, Zhu J. Differential repression of human and mouse TERT genes during cell differentiation. Nucleic Acids Res 2009; 37: 2618-2629.
25. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 1999; 59: 6087-6090.
26. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res 2000; 60: 537-541.
27. Nomoto K, Maekawa M, Sugano K, Ushiama M, Fukayama N, Fujita S, et al. Methylation status and expression of human telomerase reverse transcriptase mRNA in relation to hypermethy-lation of the p16 gene in colorectal cancers as analyzed by bisulfite PCR-SSCP. Jpn J Clin Oncol 2002; 32: 3-8.
28. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 2002; 101: 335-341.
29. Guilleret I, Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res 2003; 289: 326-334.
30. Guilleret I, Benhattar J. Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem Biophys Res Commun 2004; 325: 1037-1043.
31. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 2007; 67: 194-201.
32. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 2001; 98: 3826-3831.
33. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M, Ségal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci USA 2001; 98: 6662-6667.
34. Liu L, Saldanha SN, Pate MS, Andrews LG, Tollefsbol TO. Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 2004; 41: 26-37.
35. Love WK, Deangelis JT, Berletch JB, Phipps SM, Andrews LG, Brouillette WJ, et al. The novel retinoid, 9cUAB30, inhibits telomerase and induces apoptosis in HL60 cells. Transl Oncol 2008; 1: 148-152.
36. Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem 2001; 276: 29994-30001.
37. Pendino F, Sahraoui T, Lanotte M, Ségal-Bendirdjian E. A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation. Leukemia 2002; 16: 826-832.
38. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
39. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner P, et al. A retinoid acid 'resistant' t(15;17) acute promyelo-cytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 1992; 6: 1281-1287.
40. Pendino F, Dudognon C, Delhommeau F, Sahraoui T, Flexor M, Bennaceur-Griscelli A, et al. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene 2003; 22: 9142-9150.
41. Ségal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995; 218: 201-212.
42. Sandoval J, Rodriguez JL, Tur G, Serviddio G, Pereda J, Boukaba A, et al. RNAPol-ChIP: a novel application of chromatin immuno-precipitation to the analysis of real-time gene transcription. Nucleic Acids Res 2004; 32: e88.
43. de Thé H, Vivanco-Rulzo MM, Thiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid response element in the retinoic acid receptor b gene. Nature 1990; 343: 177-180.
44. Gunes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000; 60: 2116-2121.
45. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000; 28: 669-677.
46. Yang L, Han Y, Saurez SF, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-876.
47. Sugita M, Tanaka N, Davidson S, Sekiya S, Varella-Garcia M, West J, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet 2000; 117: 9-18.
48. Gu W, Chen Z, Hu S, Shen H, Qiu G, Cao X. Changes in expression of WT1 isoforms during induced differntiation of the NB4 cell line. Haematologica 2005; 90: 403-405.
49. Liu L, Berletch JB, Green JG, Pate MS, Andrews LG, Tollefsbol TO. Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol Cancer Ther 2004; 3: 1003-1009.
50. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659-667.
51. Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin repression. Oncogene 2009; 28: 2046-2050.
52. Renaud S, Bosman FT, Benhattar J. Implication of the exon region in the regulation of the human telomerase reverse transcriptase gene promoter. Biochem Biophys Res Commun 2003; 300: 47-54.